Liraglutide Reduces Sleep Apnea Severity in Obese COPD Patients: Study
Denmark: A recent exploratory analysis published in Clinical Obesity has found that liraglutide, a GLP-1 receptor agonist commonly used for weight management, may significantly reduce the severity of obstructive sleep apnea (OSA) and improve certain aspects of quality of life in individuals with obesity and chronic obstructive pulmonary disease (COPD).
The study led by Sofie Krogh Wolsing from the University of Southern Denmark suggests that liraglutide may have a therapeutic role in patients with coexisting respiratory and metabolic disorders.
Obstructive sleep apnea commonly occurs alongside obesity and COPD, forming a high-risk combination linked to increased morbidity, mortality, and reduced quality of life. Although weight-loss therapies are known to improve OSA, their effectiveness in patients with concurrent COPD has been unclear. To explore this, researchers performed a secondary exploratory analysis of a randomized controlled trial conducted at two Danish hospitals.
The study enrolled 40 participants aged 40–70 years with a BMI above 27 and diagnosed with COPD. They were randomly assigned to receive either liraglutide (up to 3.0 mg subcutaneously) or placebo for 40 weeks. OSA prevalence and severity were assessed at baseline and study completion using overnight cardiorespiratory monitoring, measuring apnea-hypopnea index (AHI) and oxygen desaturation index (ODI). Daytime sleepiness and quality of life were evaluated using validated questionnaires.
The researchers reported the following findings:
- At baseline, obstructive sleep apnea was highly prevalent, affecting 84% of the participants.
- After 40 weeks, liraglutide treatment led to a significant reduction in OSA severity compared to placebo.
- There was an average reduction of nearly 10 events per hour in both the apnea-hypopnea index and oxygen desaturation index.
- These improvements indicate better nighttime breathing and fewer oxygen desaturation episodes.
- No significant difference was observed in daytime sleepiness between the liraglutide and placebo groups.
- Liraglutide treatment was associated with improvements in certain domains of health-related quality of life.
- Participants reported better general health perception following treatment.
- Improvement was also seen in physical role functioning, reflecting a positive impact on daily activities and overall well-being.
The authors noted that coexisting OSA and COPD pose significant management challenges with limited treatment options. Their findings indicate that liraglutide may be a useful adjunct therapy in this group, given its benefits on both weight and respiratory parameters.
The study adds to evidence supporting the wider clinical role of GLP-1 receptor agonists beyond glycemic control and weight loss. However, the small sample size warrants cautious interpretation, and larger trials are needed to validate these findings and clarify liraglutide’s role in patients with overlapping obesity, COPD, and OSA.
Overall, the results highlight the need for integrated management strategies in complex comorbid conditions and highlight the potential of pharmacological interventions to improve clinical outcomes and quality of life.
Reference:
Wolsing, S. K., Altintas Dogan, A. D., Juhl, C. B., Hess, S., Jensen, T. T., Bladbjerg, E. M., & Hilberg, O. (2026). Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial. Clinical Obesity, 16(2), e70079. https://doi.org/10.1111/cob.70079
Next Story